Free option on their own operations: management describes a real capability it already owns that could serve a second, m
The model's full reasoning — Q1 2016 call → NOWe need answer YES or NO based on transcript. Need identify if management describes existing capability used for second larger purpose and begun converting. Let's examine. Company Curis. Programs: CUDC-907 (cancer drug) Phase 2, CA170 (oral checkpoint antagonist) entering clinic, Erivedge partnered. Also IRAK4 inhibitor. Question asks: SOMETHING THE COMPANY ALREADY OWNS AND ALREADY OPERATES FOR ITS EXISTING BUSINESS HAS TURNED OUT TO BE USEFUL FOR A SECOND, MUCH LARGER PURPOSE — and that company has recently BEGUN turning that second use into real business, without having had to build a new company. Need see if management conveys such. Possibly about CUDC-907 originally for DLBCL but now found MYC alterations, used for solid tumors? Or CA170? Let's parse. Transcript: "Our most advanced program is CUDC-907 and it is being tested in ongoing Phase 2 ... relapsed refractory DLBCL." Phase 1 results, responses correlated with MYC alterations. "In light of these findings, we designed our Phase 2 study ... to specifically treat roughly one-third of DLBCL patients who have MYC alterations... expected to increase probability." Also "examination of CUDC-907 for treatment of patients with solid tumors in our independent Phase 1 trial is ongoing and we have now limited enrollment in this study to patients with solid tumors that harbor alterations of the MYC oncogene or to patients with NUT midline carcinoma." This could be capability (drug CUDC-907) developed for DLBCL, now useful for MYC-altered solid tumors? Second use bigger? Management says "solid tumors" maybe larger market. But is it already converting? They limited enrollment in solid tumor trial to MYC altered. That's clinical trial, not business revenue. Not "real business" revenue. Also second use is still clinical trial, no revenue. So probably NO. CA170: first oral small molecule checkpoint antagonist, entering clinic. It targets PD-L1/2 and VISTA. Existing capability? Company has collaboration with Aurigene? They have rights. But not an existing working capability for established business? It's a new drug candidate entering clinic. Not built and operating for existing business. No. Erivedge: partner Genentech/Roche commercialized for BCC. Now Roche initiated studies outside BCC - myelofibrosis and IPF. Company owns royalty rights on Erivedge net sales.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| HUYA | HUYA Inc. | Q4 2023 | 2024-03-19 | C |
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| GGR | Gogoro Inc. | Q1 2023 | 2023-05-11 | D |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| RELY | Remitly Global, Inc. | Q4 2021 | 2022-03-02 | B |
| PRPO | Precipio, Inc. | Q3 2018 | 2018-11-19 | D |
HCKT · Q1 2024 → YESThe question is about whether management describes something the company already owns and operates that has turned out useful for a second, much larger purpose, and they've begun turning that into rea...
HUYA · Q4 2023 → YESThe question is whether management describes something the company already owns and operates that has turned out useful for a second, much larger purpose, and they've begun turning that into real busi...
SANG · Q2 2024 → YESThe question is about whether management describes something the company already owns and operates that has turned out useful for a second, much larger purpose, and they've begun turning that into rea...